Consolidated revenue of Rs 2,865 crore, up 3.5 percent from a year ago was also lower-than-expected.

Analysts on average had expected the pharma major to report a net profit of Rs 428 crore on revenue of Rs 2,913 crore.

While overall expenses rose in Q3, in the year-ago quarter, Dr Reddy's earnings were boosted by exclusivity of Zyprexa generic. Teva Pharmaceutical Industries and Dr Reddy's had in Oct 2011 launched a generic version of Eli Lilly's Zyprexa (schizophrenia treatment drug) and were awarded a 180-day period of marketing exclusivity.